MEDI2070 is an experimental Crohn’s disease and ulcerative colitis drug developed by the London-based pharmaceutical company AstraZeneca.
Here’s what you need to know:
1. Allergan paid $250 million upfront during this transaction.
2. Allergan has agreed to pay AstraZeneca additional payments of up to $1.27 billion, should the drug hit certain product development and sales milestones.
3. MEDI2070 is in a phase IIb study concerning Crohn’s disease treatment. The drug is also ready to begin phase II trials for ulcerative colitis treatment.
More articles on gastroenterology and endoscopy:
Predictive overbooking maximizes endoscopy clinic scheduling: 5 study insights
GI societies advocate for increased coverage of CRC screening, treatment: 4 notes
What is the future of colorectal cancer screening? Still colonoscopy, says Dr. David A. Johnson
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.